Prognostic factors and the impact of adjuvant chemotherapy on recurrence and survival in stage I non-small cell lung cancer: A real-world study

Year 2025, Volume: 11 Issue: 2, 351 - 362

Akif Doğan , Sedat Yıldırım , Hande Nur Erölmez , Goncagül Akdağ , Zeynep Yüksel Yaşar , Ezgi Türkoğlu , Nurullah İlhan , Seval Ay Ersoy

https://doi.org/10.18621/eurj.1633305

Abstract

Objectives: Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality. Despite curative surgery, recurrence is common in Stage I NSCLC, highlighting the need for improved prognostic classification. This study aims to evaluate the key pathological factors affecting recurrence and survival and to investigate the potential benefit of adjuvant chemotherapy (ACT) in patients with Stage I NSCLC.

Methods: A retrospective analysis was conducted on patients with Stage I NSCLC who underwent curative surgery between 2010 and 2024. Demographic and disease-related prognostic factors were assessed. The impact of these factors, along with adjuvant chemotherapy (ACT), on overall survival (OS) and disease-free survival (DFS) was analyzed.

Results: A total of 95 patients were included in the study, with a median follow-up period of 47 months. Recurrence occurred in 35.8% of patients, and 16.8% died. The five-year OS and DFS rates were calculated as 76.4% and 67.9%, respectively. Spread through air spaces (STAS) was identified as an independent prognostic factor associated with an increased risk of recurrence. While OS was shorter in patients with LVI positivity, it was not determined to be an independent prognostic factor. Visceral pleural invasion (VPI) did not demonstrate a significant prognostic impact on survival or recurrence. The effect of ACT on OS and DFS was evaluated, but no survival advantage was observed.

Conclusions: Certain pathological factors influence survival and recurrence in Stage I NSCLC. While STAS was identified as an independent prognostic factor, ACT did not provide a significant benefit for OS or DFS. These findings emphasize the importance of individualized treatment approaches and close oncological follow-up after surgery. Future studies should incorporate novel and effective biomarkers, such as circulating tumor DNA, to optimize adjuvant therapy decisions.

Keywords

Non-small cell lung cancer, spread through air spaces, recurrence, survival, prognostic factors, lymphovascular invasion, adjuvant chemotherapy

Ethical Statement

This study was approved by the Kartal Dr. Lütfi Kırdar City Hospital Scientific Research Ethics Committee (Decision no: 2025/010.99/12/35 and date: 24.01.2025) and was conducted in accordance with the principles of the Declaration of Helsinki.

References

• 1. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10-45. doi: 10.3322/caac.21871.
• 2. Stirling RG, Chau C, Shareh A, Zalcberg J, Fischer BM. Effect of Follow-Up Surveillance After Curative-Intent Treatment of NSCLC on Detection of New and Recurrent Disease, Retreatment, and Survival: A Systematic Review and Meta-Analysis. J Thorac Oncol. 2021;16(5):784-797. doi: 10.1016/j.jtho.2021.01.1622.
• 3. Choi PJ, Jeong SS, Yoon SS. Prognosis of recurrence after complete resection in early-stage non-small cell lung cancer. Korean J Thorac Cardiovasc Surg. 2013;46(6):449-56. doi: 10.5090/kjtcs.2013.46.6.449.
• 4. Dediu M, Ion O, Ion R, et al. Impact of adjuvant chemotherapy in stage IB non-small-cell lung cancer: an analysis of 112 consecutively treated patients. J BUON. 2012;17(2):317-322.
• 5. Mollberg NM, Bennette C, Howell E, Backhus L, Devine B, Ferguson MK. Lymphovascular invasion as a prognostic indicator in stage I non-small cell lung cancer: a systematic review and meta-analysis. Ann Thorac Surg. 2014;97(3):965-971. doi: 10.1016/j.athoracsur.2013.11.002.
• 6. Oven Ustaalioglu BB, Unal OU, Turan N, et al. Prognostic factors for lymph node negative stage I and IIA non-small cell lung cancer: multicenter experiences. Asian Pac J Cancer Prev. 2013;14(11):6287-6292. doi: 10.7314/apjcp.2013.14.11.6287.
• 7. Tao H, Hayashi T, Sano F, et al. Prognostic impact of lymphovascular invasion compared with that of visceral pleural invasion in patients with pN0 non-small-cell lung cancer and a tumor diameter of 2 cm or smaller. J Surg Res. 2013;185(1):250-254. doi: 10.1016/j.jss.2013.05.104.
• 8. Neri S, Yoshida J, Ishii G, et al. Prognostic impact of microscopic vessel invasion and visceral pleural invasion in non-small cell lung cancer: a retrospective analysis of 2657 patients. Ann Surg. 2014;260(2):383-388. doi: 10.1097/sla.0000000000000617.
• 9. Ding Y, Li J, Li X, Xu M, Geng H, Sun D. Impact of preoperative biopsy on tumor spread through air spaces in stage I non-small cell lung cancer: a propensity score-matched study. BMC Pulm Med. 2022;22(1):293. doi: 10.1186/s12890-022-02090-z.
• 10. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552-3559. doi: 10.1200/jco.2007.13.9030.
• 11. Strauss GM, Herndon JE, 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26(31):5043-5051. doi: 10.1200/jco.2008.16.4855.
• 12. Riely GJ, Wood DE, Ettinger DS, et al. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(4):249-274. doi: 10.6004/jnccn.2204.0023.
• 13. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39-51. doi: 10.1016/j.jtho.2015.09.009.
• 14. Travis WD. The 2015 WHO classification of lung tumors. Pathologe. 2014;35 Suppl 2:188. doi: 10.1007/s00292-014-1974-3.
• 15. Chen D, Mao Y, Wen J, et al. Tumor Spread Through Air Spaces in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Ann Thorac Surg. 2019;108(3):945-954. doi: 10.1016/j.athoracsur.2019.02.045.
• 16. Hashinokuchi A, Akamine T, Toyokawa G, et al. Impact of the distance of spread through air spaces in non-small cell lung cancer. Interdiscip Cardiovasc Thorac Surg. 2024;40(1):ivae181. doi: 10.1093/icvts/ivae181.
• 17. Li J, Wang Y, Li J, Cao S, Che G. Meta-analysis of Lobectomy and Sublobar Resection for Stage I Non-small Cell Lung Cancer With Spread Through Air Spaces. Clin Lung Cancer. 2022;23(3):208-213. doi: 10.1016/j.cllc.2021.10.004.
• 18. Lin X, Xu H, Chen J, Wu J, Lin J, Wu H. The prognosis and treatment consideration for non-small cell lung carcinoma patients with tumor size of >2.0-3.0 cm and visceral pleural invasion: a SEER-based study. Transl Cancer Res. 2024;13(11):6004-6017. doi: 10.21037/tcr-24-33.
• 19. Wang G, Ye YQ, Xie BL, Lai XM, Zhong SP. Investigation of the non-small cell lung cancer patients with bronchus involvements: A population-based study. Clin Respir J. 2023;17(9):941-950. doi: 10.1111/crj.13683.
• 20. Nagano M, Sato M. Impact of surgical margin after sublobar resection of lung cancer: a narrative review. J Thorac Dis. 2023;15(10):5750-5759. doi: 10.21037/jtd-23-711.
• 21. Sawabata N, Miyaoka E, Asamura H, et al. Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. J Thorac Oncol. 2011;6(7):1229-1235. doi: 10.1097/JTO.0b013e318219aae2.
• 22. Tantraworasin A, Saeteng S, Lertprasertsuke N, Arayawudhikule N, Kasemsarn C, Patumanond J. Completely resected n0 non-small cell lung cancer: prognostic factors affecting long-term survival. ISRN Surg. 2013;2013:175304. doi: 10.1155/2013/175304.
• 23. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004;350(17):1713-1721. doi: 10.1056/NEJMoa032792.
• 24. Hamada C, Tanaka F, Ohta M, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol. 2005;23(22):4999-5006. doi: 10.1200/jco.2005.09.017.
• 25. Ak N, Ozkan B, Yenigun MB, et al. The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study. J BUON. 2021;26(3):819-29.
• 26. Lu J, Feng Y, Guo K, Sun L, Ruan S, Zhang K. Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2024;150(1):25. doi: 10.1007/s00432-023-05550-z.